Acute Myeloid Leukemia: Diagnosis, Prognosis, Treatment and Outcomes


Rina Kansal, M.D. – The University at Buffalo, Buffalo, New York, USA; Associate Medical Director, Molecular Oncology and Genetics, Diagnostic Laboratories, Blood Center of Wisconsin, USA

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062020; MED018000

This book is written by multidisciplinary specialists who diagnose and treat acute myeloid leukemia (AML) patients and is meant for anyone interested in the clinical care of patients with hematologic malignancies, including students and trainees. The 21 contributors for this book include expert clinicians in leukemia and hematologic malignancies, infectious diseases, pharmacological drug administration, pathology, cytogenetics, molecular genetics, and artificial intelligence, and one medical student and advanced trainees. The book comprises nine chapters, starting with a comprehensive overview of the global epidemiology, etiology, prognosis, treatment, and outcomes in patients with AML. Chapter 2 describes the classification of myeloid neoplasms, including AML, with a historical perspective and current diagnostic criteria. This chapter describes the fifth edition of the World Health Organization (WHO) classification and the updates from the revised fourth edition of the WHO classification. It compares the similarities and differences from the International Consensus Classification. Chapter 3 is focused on genetic evaluation in AML, emphasizing cytogenetic techniques, with numerous illustrations depicting genetic abnormalities in AML. Chapter 4 discusses measurable residual disease (MRD) in AML and explains the approaches and current guidelines for MRD detection by multiparametric flow cytometry and molecular techniques, emphasizing the pre-analytical, analytical, and post-analytical factors in evaluating MRD, with illustrations for essential concepts. Chapter 5 describes clonal hematopoiesis and its role in the development of myeloid neoplasms. Chapter 6 discusses inherited germline predisposition to myeloid malignancies, including inherited bone marrow failure syndromes and syndromic and non-syndromic predisposition syndromes for hematologic malignancies. Chapter 7 describes and illustrates novel therapeutic agents in AML, including genetically-targeted therapies, non-genetically targeted therapies, and immunotherapies. Chapter 8 covers the management of infectious complications in patients with AML, and Chapter 9 introduces the reader, with many illustrations, to the emerging applications of artificial intelligence in diagnostic hematopathology.

Table of Contents



Chapter 1. Acute Myeloid Leukemia: A Global Perspective of Epidemiology, Prognosis, Treatment and Outcomes
Hui Wei1,2, MD, PhD
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2Tianjin Institutes of Health Science, Tianjin, China

Chapter 2. The Diagnostic Classification of Myeloid Neoplasms with Emphasis on Acute Myeloid Leukemia
Rina Kansal, MD
University at Buffalo, Buffalo, New York, USA

Chapter 3. Genetic Evaluation in Acute Myeloid Leukemia
Grace E. Weber1, Ph.D. and Shashirekha Shetty1,2, Ph.D.
1Cytogenetics Laboratory, Center for Human Genetics, Department of Pathology, University Hospitals, Cleveland, Ohio, USA
2Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA

Chapter 4. Measurable Residual Disease in Acute Myeloid Leukemia
Ross Lindell-Innes1, Doctor and Dipti Talaulikar1,2, Professor
1Department of Haematology, ACT Pathology, Canberra Health Services, Canberra, ACT, Australia
2College of Health and Medicine, Australian National University, Canberra, ACT, Australia

Chapter 5. Clonal Hematopoiesis and Acute Myeloid Leukemia
Lia E. Jueng1 and Namrata S. Chandhok2,3
1University of Miami Miller School of Medicine, Miami, Florida, USA
2Department of Medicine, Division of Hematology, University of Miami, Miami, Florida, USA
3Sylvester Comprehensive Cancer Center, Miami, Florida, USA

Chapter 6. Inherited Germline Predisposition in Hematological Malignancy
Mark G. Faber, Elizabeth A. Griffiths, Arya Mariam Roy, Muhammad Salman Faisal and Riya Patel
Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Chapter 7. Novel Therapeutics in the Treatment of Acute Myeloid Leukemia
Jacob Jahn and Justin Taylor, MD
Justin Taylor Laboratory, Sylvester Comprehensive Cancer Center, Biomedical Research Building, Miami, Florida, USA

Chapter 8. Acute Myeloid Leukemia and the Propensity for Infectious Complications
Mohammed Raja1, MD and Anthony D. Anderson2, PharmD, BCIDP
1Transplant Infectious Diseases and Immunocompromised Host Service, Department of Medicine, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida, USA
2Department of Pharmacy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida, USA

Chapter 9. Clearing Barriers to the Application of Artificial Intelligence in Hematopathology
Yukako Yagi1, Yuefeng Yin2, Nilay Bakoglu1 and Xuejun Shao3
1Memorial Sloan Kettering Cancer Center, New York, USA
2Bionovation Biotech Inc., San Diego, USA
3Children’s Hospital of Soochow University, China


Editor’s ORCID iD

Rina Kansal, M.D.0000-0003-4289-3057

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!